Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

April 2024

Guselkumab provides durable improvement across psoriatic arthritis disease domains: Post hoc analysis of a Phase 3, randomised, double-blind, placebo-controlled study

RMD Open 2024;10:e003977 doi: 10.1136/rmdopen-2023-003977

Shawi M,

Xu XL,

Nash P,

Mease PJ,

Helliwell PS

Significant improvements in overall disease activity, enthesitis and dactylitis, and skin psoriasis were observed by Week 8 and maintained or improved through Week 100 in both guselkumab treatment groups. Coates et al conducted a post-hoc analysis of the Phase 3 DISCOVER-2 trial to investigate the long-term (100-week) efficacy of guselkumab across GRAPPA-identified PsA domains.

Keywords:

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update

Ann Rheum Dis 2024 doi: 10.1136/ard-2024-225531 Epub ahead of print

Eder L,

Mauro D,

Nash P,

van der Helm-van Mil A,

Zabotti A,

van der Heijde D,

Smolen JS

The 2023 EULAR recommendations provided an updated consensus on the pharmacological management of PsA with a new overarching principle and recommendation for 2023. Recent MOA safety data emphasised the importance of patient-specific benefit-risk profiling in JAKi therapy, and extra-musculoskeletal (MSK) manifestations related to PsA should be considered during drug selection.

Keywords:

December 2023

関節リウマチ、乾癬性関節炎、強直性脊椎炎患者におけるウパダシチニブ臨床試験におけるMACE と VTE

RMD Open 2023; 9(4):e003392 doi 10.1136/rmdopen-2023-003392

Choy E,

Nash P,

Lippe R,

Khan N,

Shmagel AK,

Palac H,

Suboticki J,

Curtis JR

Rates of MACE and VTE events in patients with RA or PsA treated are consistent across 15 mg and 30 mg doses of upadacitinib, and comparable with active comparators adalimumab and MTX. Several risk factors were also identified for MACE and VTE events in patients with RA.

Keywords:

August 2023

2つのフェーズ3試験解析からみた乾癬性関節炎患者におけるイキセキズマブの体軸症状への効果: SPIRIT-P1 と SPIRIT-P2

Ther Adv Musculoskelet Dis. 2023;15:1759720X231189005 doi: 10.1177/1759720X231189005

Bolce R,

Park SY,

Nash P,

Post-hoc analysis of SPIRIT-P1 and SPIRIT-P2 concludes that ixekizumab (IXE) is effective in improving axial symptoms in patients with active PsA presenting with axial manifestations.

Keywords:

April 2023

活動性乾癬性関節炎患者の指炎に対するセクキヌマブFUTURE 5 試験

Clin Exp Rheumatol. 2023 doi: 10.55563/clinexprheumatol/vezf95

Kirkham B,

Nash P,

Reina D,

The presence of dactylitis was associated with a higher disease burden in patients with PsA compared with those without dactylitis at baseline. The aim of this study was to evaluate the efficacy of secukinumab in patients with dactylitis at baseline over 2 years.

Keywords:

March 2023

関節リウマチ、乾癬性関節炎、強直性脊椎炎を対象とした１５０００人年におよぶウパダシチニブの安全性

RMD Open. 2023;9(1):e002735 doi: 10.1136/rmdopen-2022-002735

Nash P,

Liu J,

Palac H,

Shaw T,

Mease PJ,

Guttman-Yassky E

Integrated analysis of the safety profile of upadacitinib demonstrates that it was generally well-tolerated in RA, PsA, AS and AD, with no new safety risks identified, compared with previous reports.

Keywords:

December 2022

合成および生物学的抗リウマチ薬によるRAマネジメントに関する 2022 EULAR リコメンデーション

Ann Rheum Dis. 2022. Epub ahead of print [05/12/2022] doi: 10.1136/ard-2022-223356

Pope JE,

Balsa A,

Buch MH,

Li Z,

Nash P,

Poor G,

van der Helm-van Mil A,

Smolen, et al. provide a 2022 update of the EULAR recommendations for the management of RA with synthetic and biological DMARDs.

Keywords:

EULAR

November 2022

Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study

Rheumatol Ther. 2022. Epub ahead of print doi: 10.1007/s40744-022-00498-x

Combe BG,

Tanaka Y,

Buch MH,

Nash P,

Xia K,

Emoto K,

Kano S,

Hendrikx TK,

Landewé RBM,

Aletaha D

Post hoc analysis from the FINCH 1 study highlights filgotinib as a potential beneficial treatment option for patients with RA who have had inadequate response to MTX and have high risk of disease progression and poor prognosis.

Keywords:

September 2022

乾癬性関節炎におけるウパダシチニブの単剤治療または非生物学的製剤との併用療法

Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keab905

Nash P,

Kato K,

McDearmon-Blondell EL,

Feng D,

In this investigation, upadacitinib showed comparable efficacy as monotherapy and in combination with nbDMARDs in PsA. In coming to this conclusion investigators aimed to assess the efficacy and safety of upadacitinib as monotherapy or in combination with nbDMARDs in patients with PsA.

Keywords:

炎症疾患におけるインターロイキン-6およびインターロイキン-6受容体阻害に関するとコンセンサス: アップデート

doi: 10.1136/ard-2022-222784.

Choy EH,

Combe B,

Crow MK,

Emery P,

Gabay C,

Nash P,

Poor G,

Blocking the IL-6R is a major therapeutic advance for many diseases in adults and children. Updated consensus statement provides guidance to rheumatologists and other experts, as well as patients and administrators, on managing patients with the use of drugs blocking the IL-6 pathway.

Keywords:

IL-6,
Review